Dysregulated B-cell receptor (BCR) signaling is considered a potent contributor to tumor survival in different subtypes of B-cell non-Hodgkin lymphomas (B-NHLs). This evidence concerns the gene BCR and B-cell non-Hodgkin lymphoma.